Watson Biology 5 senior executives are from cloud technology

The company's actual control of the vacancy, 6 years only research and sales of two products financial weekly reporter/Zhou Chiqiu after the galactic magnets, the capital market has also discovered a lack of controlling shareholders and the actual control of the company has successfully landed on the gem. September 13, the SFC website issued a notice, Yunnan Watson Biotechnology Co., Ltd. (hereinafter referred to as Watson Biology) was approved.　　Thus, the lack of the actual helm, operating two types of vaccines, private companies will become Yunnan's first gem listed companies.　　It is worth mentioning that earlier, because of the Pacific Securities listing events in the capital market uproar of cloud technology has also been in Watson's life in the past and this lifetime played an important role.　　Fundamentals, the flagship of the second category of vaccine development and production of Watson biology since the establishment of 2001, independent research and development and sales of only two products.　　Still, the success of the IPO will make the company's shareholders soar. The lack of actual control of the stock rights dispersed as at the date of the prospectus, Watson has a total of 22 shareholders, of whom three are corporate shareholders.　　It is important to mention that, from the prospectus, Watson's biology not only lacks the controlling shareholder and the actual control person, but also has a more fragmented shareholding structure. Most of the natural person shareholders are company executives. Company chairman and general Manager Li Yunchun holds 15.0458 million shares, accounting for more than 20.06%, the company director Liu Junhui holding 11.3906 million shares, accounting for more than 15.19%.　　Watson biological director and deputy general Manager of Chen Lijia, Liu Hongyan, respectively, holding 8.2315 million shares of the company and 6.9662 million shares, the total holdings accounted for 20.27% of the shares.　　As a result, none of the major shareholders of Watson's biology can form a real control of the company through direct or indirect holding of shares in the company or through investment relations. After the issue is completed, the shares held by the shareholders will be further diluted. Watson issued a total of 75 million shares before the issue, the company intends to issue 25 million shares.　　After the issuance of the above executive shareholder share will be diluted to 15.05%, 11.39%, 10.98%, 6.97%.　　In this respect, Watson said: The company's ownership structure is relatively dispersed, will make the company may become the object of acquisition, once the company is acquired, may give the company business or management, and so have a certain impact.　　There are two messages in the Watson's 361-page pre-disclosure material, which has a lot to do with cloud technology.　　The 76th page content shows: Bervott Biology 2004 7-August by Let Yun Big Technology Co., Ltd. held Watson Biology limited 45% Equity, September 2004 by let Tao smell of Watson Biological Limited 5% shares (a total of 50% equity) is actually Li Yunchun, Chen Lijia, Liu Hongyan three people were let. The 81st page shows: September 13, 2004, Tao will hold the Watson biological 5% stake to 100,000 yuan to Bervott biology, to obtain equity transfer income of 100,000 yuan. While the 2002 Tao smelled the 5% Watson's biological stake in the creature's possession, aboutDingtao the 135,000-dollar claim to the Lee-no creature and the transfer of equity that should be paid to the Lee-no organism, that is, the cost of acquiring the stake is 135,000 yuan.　　The equity transfer income is 100,000 yuan, and the cost of acquiring equity is 135,000 yuan. From this point of view, the above named Tao, the natural person shareholder was originally at a discount to withdraw Watson biology. Bervott Biology is the original shareholder of Watson.　　Pre-disclosure materials show that Watson's biological predecessor Watson Limited, the founder of Li Yunchun Holdings of the run of the pharmaceutical industry, founder Chen Lijia Holdings of Bervott Biology and Yun-SAARC Pharmaceutical Co., Ltd. was established in January 2001, the registered capital of 1.26 million yuan. The above mentioned Cloud Technology Co., Ltd. is just another major role in the Pacific Securities listing event.　　And Watson's biological landing on the gem of the difference is that cloud technology has long been retired from the city for many years.　　It is puzzling, however, that in Watson's bio-disclosure materials, there is no mention of the origins of the 45% stake in Watson's biology and the details of the transfer.　　As for why Cloud technology will transfer Watson's bio-equity in 2004 7-August, the pre-disclosure only indicates that "the overall exit from the vaccine industry is due to changes in the technology strategy of the Cloud". September 15, a weekly newspaper reporter Call Watson biology director of the secret office was the staff told: "The company two contact per capita on business outside." "When asked about the change of Watson's bio-equity ownership by Cloud technology, the staff said:" Everything is based on the prospectus. At the same time, keep asking reporters: "You are the media."　　"Most executives are looking at the Watson's prospectus, and a weekly newspaper reporter found that although Watson's biology has no explanation for the company's former big shareholder cloud-tech relationship, many executives, including company chairman Li Yunchun, have a big background.　　August 2002, cloud technology and related companies to acquire 100% stake in Dalian Han Xin, of which the cloud of science and technology capital of 40 million yuan, accounting for 80% of the equity ratio.　　Watson's bio-prospectus content shows: In view of Cloud Technology 2002 acquisition of Dalian Han Letter, also indirectly hold Watson limited part of the stock, cloud science and technology in the system to select familiar with biotechnology, vaccine development and production experts Li Yunchun, Chen Lijia to participate in Dalian Han Letter management work.　　August 2002, Li Yunchun, Chen Lijia as the cloud of science and technology dispatched personnel to serve as the director of Dalian Sino-letter.　　In February 2005, Chen Lijia and Li Yunchun respectively were recruited as Chairman and general manager and vice chairman of Dalian Han Xin, Liu Hongyan as director of the company.　　March 2006, Chen Lijia continued to serve as general manager of Dalian Hanshin, Li Yunchun, Liu Hongyan from Dalian Han letter left.　　At the end of 2007, Chen Lijia to Dalian, the letter of resignation, June 2008, Dalian Han letter to complete the industrial and commercial registration of the change procedures, so far Chen Lijia no longer as Dalian Han letter any position. It is worth mentioning that Dalian Hanshin from 2007 to 2009 as suppliers to Watson biologyThe sale of hepatitis B vaccine products is sold by Watson Biology as a proxy vaccine product. In addition, Watson Bio-finance director Wang Yunhua was a deputy manager of the finance Department of Kunming Yun da Technology Industry Co., Ltd.　　Wu Kai, director of testing technology and standards, has served in the Pharmaceutical Center of the Research Institute of Yun DA Technology Co., Ltd.　　Deng Zhimin, a director of the Board of Directors, deputy general manager and general manager of Yun DA Technology Co., Ltd., is currently the general manager of Yunnan Yun da Investment Holdings Limited.　　In addition, Watson biological director Liu Junhui has worked in another two-class vaccine for new shares of intelligent flying creature, as director and deputy general Manager. 6 years only research and sales two products from the fundamental point of view, Watson biology is mainly engaged in the development of the second category of vaccine products, production and sales.　　It is necessary to mention that, although the company was established in January 2001, but the current Watson bio-research and sales of products only two, respectively, Hib, lyophilized A, C meningococcal polysaccharide combined vaccine. From the point of view of time, the vaccine Hib produced by the company was released to the market in September 2007.　　It is known that Hib vaccine is called Haemophilus influenzae type B combined vaccine for the prevention of meningitis, pneumonia, sepsis, cellular inflammation, arthritis and pharyngitis, and other infectious diseases caused by Haemophilus influenzae type B. In 2008 and 2009, Watson's bio realized income of 184 million yuan and 239 million yuan respectively.　　One of the company's Hib income is 84.08 million yuan, 156 million yuan, accounting for 45.68%, 65.26%.　　In the company's own products to achieve sales to carry out the sale of the banner, Watson Bio-agent through the sale of hepatitis A, hepatitis B vaccine to maintain operations.　　From 2007 to 2009, the company agent Hepatitis A vaccine sales income is 77.33 million yuan, 72.07 million yuan and 34.99 million yuan, the agent hepatitis B vaccine sales income is 25.89 million yuan, 14.68 million yuan, 3.55 million yuan respectively. In the above year, Watson's living business income is 129 million yuan, 184 million yuan and 239 million yuan respectively.　　It is worth mentioning that, Watson agent of hepatitis B vaccine suppliers Dalian Han letter is the company's three top executives shareholder Li Yunchun, Chen Lijia, Liu Hongyan has stationed in the company.　　Chairman Li Yunchun with six shareholder market capitalisation even though Watson's biology lacks controlling shareholder and the actual control person, but the success of the IPO still does not hinder the company 22 shareholder to put on the wealth myth. From the view of shareholding, Watson 22 of the shareholders to remove 3 corporate shareholders, the rest are natural shareholders. Li Yunchun, chairman and general manager of the company as the largest shareholder, a total of 15.0458 million shares, the shareholding ratio of 20.06%, the company director Liu Junhui as the second largest shareholder, holding 11.3906 million shares, accounting for more than 15.19%.　　Yuxi Real Estate shares 9.5273 million shares, accounting for 12.7%. In addition, Watson biological two other corporate shareholders are venture capital institutions, the HONGTA venture capital and Changan Ventures respectively hold the company shares 7.5 million shares, 3.75 million shares.　　The prospectus shows that in 2009 Watson's earnings were 1.02 yuan per share, with earnings of 0.765 yuan per share diluted. As of September 14, wind information showed that the gem P/E ratio (TTM, arithmetic averaging method) is 71.43 times times.　　The combination of the two, the financial weekly newspaper reporter estimated Watson bio-price of 54.64 yuan/share. From this point of view, after Watson's successful listing, the company's large and small shareholders holding the value of the shares will achieve explosive growth. Company chairman and general Manager Li Yunchun value will be expected to reach 822 million yuan, the company's director Liu Junhui value will reach 622 million yuan.